Targeting ABCB5 for cancer therapy

• US 9,266,946 B2
• Filed: 04/14/2014
• Issued: 02/23/2016
• Est. Priority Date: 04/12/2007
• Status: Active Grant

• Current Assignee: Brigham and Women's Hospital Incorporated
• Original Assignee: Brigham and Women's Hospital Incorporated
• Inventors: Frank, Markus H., Frank, Natasha Y., Sayegh, Mohamed H.
• Primary Examiner(s): Huff, Sheela J
• Application Number:
  US14/251,932
• Publication Number:
  US 20140302031A1
• Time in Patent Office: 680 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 31/713 Double-stranded nucleic acids or oligonucleotides
• CPC Class Codes: A61K 38/47 acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• CPC Class Codes: A61K 47/6851 the antibody targeting a determinant of a tumour cell
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 16/28 against receptors, cell surface antigens or cell surface determinants
• CPC Class Codes: C07K 2317/56 variable (Fv) region, i.e. VH and/or VL
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/732 Antibody-dependent cellular cytotoxicity [ADCC]
• CPC Class Codes: C07K 2317/734 Complement-dependent cytotoxicity [CDC]
• CPC Class Codes: C12N 15/1135 against oncogenes or tumor suppressor genes
• CPC Class Codes: C12N 2310/14 interfering N.A.
• CPC Class Codes: C12N 2310/3513 Protein; Peptide
• CPC Class Codes: C12N 2320/32 Special delivery means, e.g. tissue-specific
• CPC Class Codes: C12Y 302/02022 rRNA N-glycosylase (3.2.2.22)
• CPC Class Codes: G01N 2333/705 Assays involving receptors, cell surface antigens or cell surface determinants
• CPC Class Codes: G01N 33/574 for cancer
• CPC Class Codes: G01N 33/57492 : involving compounds localized on the membrane of tumor or cancer cells

Abstract

The invention relates to methods for treating a subject by manipulating ABCB5 on a cell as well as related products. The methods include methods of treating cancer using ABCB5 binding molecules such as antibodies and fragments thereof.

Claims

1. A method for treating a subject, comprising

systemically administering an isolated antibody that selectively binds to ABCB5 to a subject having cancer in an effective amount to treat the cancer, wherein the isolated antibody is not co-administered with a chemotherapeutic agent.

2. The method of claim 1, wherein the isolated antibody is a monoclonal antibody.

3. The method of claim 1, wherein the isolated antibody has at least one human region.

4. The method of claim 1, wherein the isolated antibody competitively inhibits binding of mAb 3C2-1D12 to ABCB5.

5. The method of claim 1, wherein the isolated antibody is of immunoglobulin class IgA, IgGb 1, IgG2, IgG3, IgG4 or IgM.

6. The method of claim 1, wherein the isolated antibody is a single chain antibody.

7. The method of claim 1, wherein the subject has melanoma.

8. The method of claim 1, wherein the subject is a human subject.

9. The method of claim 1, wherein the subject is a companion animal.

10. The method of claim 1, wherein the cancer is a cancer having cancer stem cells that express ABCB5 and is selected from the group consisting of biliary tract cancer;

brain cancer;

breast cancer;

cervical cancer;

choriocarcinoma;

colon cancer;

endometrial cancer;

esophageal cancer;

gastric cancer;

intraepithelial neoplasms;

lymphomas;

liver cancer;

lung cancer (e.g. small cell and non-small cell);

neuroblastomas;

oral cancer;

ovarian cancer;

pancreas cancer;

prostate cancer;

rectal cancer;

sarcomas;

skin cancer;

testicular cancer;

thyroid cancer; and

renal cancer.

11. The method of claim 1, further comprising, prior to the treatment of the subject detecting the presence of ABCB5 positive stem cells.

12. The method of claim 11, wherein the presence of ABCB5 positive stem cells is detected by contacting a sample from a subject with a peptide that selectively binds to ABCB5 in order to detect cells that bind to the peptide.

13. The method of claim 12, wherein the sample is a sample of a tumor mass.